Co-Investigator in the multicentric studies

•  A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion. Study coordinator
• A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. Study coordinator
• A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Co-investigator
• A 12  Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis(Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD. Treating Investigator
• A randomized, double masked , active controlled phase 3 study of the efficacy, safety and tolerability of repeteated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD) (VIEW2). Study coordinator
• A phase II  prospective , randomised , multicentric diabetic macular edema  dose ranging, comparation study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS). Co-investigator
• A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO). Treating Investigator
• Macular edema Incidence/Severity Reduction with NEVANAC^®. Phase IIIb, prospective, multicenter, double-masked, randomized, parallel group, placebo controlled study. Study coordinator
• Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN). Treating investigator
• Multicentric, phase 3, randomized, double blind, active control, 12 months follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab vs photodynamic therapy in myopic CNV. Treating investigator
• A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID). Study coordinator
• A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion (COMO). Study coordinator
• A multicenter, open-label, randomized study comparing the efficacy and safety of 700 mg Dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema. Study coordinator.
• A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess theeffectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens (POLARIS). Bayer. Sub-Investigator.
• Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS). Sub-Investigator.
• A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis. Sub-Investigator.
• A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Novartis. Sub-Investigator.
• A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety ofranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular agerelated macular degeneration (TREND). Novartis. Sub-Investigator.
• A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration (FOVISTA). Ophthotec. Study Coordinator.
• A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES). Allergan. Follow up investigator.
• Studio clinico pilota di valutazione della somministrazione topica oculare di luteina mediante iontoforesi transclerale (LUTEIN EYE) rev. IDOL  (AMD)
• Studio esplorativo randomizzato, in doppio mascherato, controllato con placebo per valutare sicurezza, tollerabilità, farmacodinamica e farmacocinetica del BI1467335 per os per 12 settimane di trattamento più 12 settimane di follow-up, in pazienti con retinopatia diabetica non proliferativa  senza edema maculare centrale ROBIN (RD)
• Studio Clinico di fase III multicentrico, randomizzato, in doppio cieco, controllato con trattamento simulato, volto a valutare la sicurezza e l’efficacia della somministrazione intravitreale di ZIMURA™ (inibitore del componente c5 del complemento) in pazienti con atrofia geografica secondaria a degenerazione maculare senile secca” . protocollo ISEE2008

• Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) Allergan.

• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF EFFICACY AND SAFETY OF 10 mg LAMPALIZUMAB INTRAVITREAL INJECTIONS ADMINISTERED EVERY 30 OR 45 DAYS TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. ROCHE.

• Cambiamenti morfologici e funzionali retinici a lungo termine dopo l’utilizzo topico di Citicolina e vitamina B12 in pazienti con retinopatia di tipo lieve e diabete tipo 1 OMK 2

• Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration  SEQUOIA/ AGN-150998  (WAMD)

• -Cross-sectional and longitudinal case–control exploratory clinical study:Morphological retinal changes in type 1 diabetes evaluated by means of multimodal imaging

• “STUDIO DI ESTENSIONE, MULTICENTRICO E IN APERTO VOLTO A VALUTARE LA SICUREZZA E LA TOLLERABILITÀ A LUNGO TERMINE DI LAMPALIZUMAB IN PAZIENTI AFFETTI DA ATROFIA GEOGRAFICA SECONDARIA A DEGENERAZIONE MACULARE LEGATA ALL’ETÀ CHE HANNO PORTATO A TERMINE UNO STUDIO PROMOSSO DA ROCHE” GX30191

• Efficacia di una formulazione, a base di curcumina, nel coadiuvare l’effetto antiedemigeno del desametasone intravitreale in soggetti affetti da edema maculare diabetico (DME) DIABEC

• Valutazione della funzione maculare e dei relativi cambiamenti della percezione visiva e della morfologia retinica dopo l’utilizzo per 6 mesi di un complemento alimentare in compresse denominato MACUPREV, in pazienti con degenerazione maculare legata all’età (MACUPREV)

• Individuazione di segni precoci di neurodegenerazione retinica e valutazione del ruolo patogenico della variabilità glicemica nei pazienti affetti da diabete mellito tipo 1 in età pediatrica DM1

• Correlazione tra la densità vascolare maculare studiata con OCT-Angiography e l’ischemic index periferico valutato con Ultra Wide Field Angiography in pazienti con Malattia di Behçet

• Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) -MACUSTAR ECR-AMD-2017-13

• A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety ofConbercept Intravitreal Injection in Subjects withNeovascular Age-Related Macular Degeneration  (CHENGDU TECHNOLOGY)Studio Clinico KHB-1802 PANDA COMBERCERT

• Studio multicentrico, in doppio cieco, randomizzato, dose-ranging volto a valutare l’efficacia e la sicurezza di conbercept per inizione intravitreale in soggetti affetti da degenerazioene maculare legata all’età neovascolare

• “A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA”   (DME).  YOSEMITE Faricimab EMD

• Studio Screening PHQ9-P  e GAD 7  Utilizzo dei questionari di screening per depressione (PHQ9-P) e ansia (GAD-7) nel management di pazienti con malattie oftalmiche croniche.

• A multicenter, open label extension study to evaluate the long-term safety and tolerability of faricimab  in patients with diabetic macular edema.  GR41987 Rhone-X.

• Studio multicentrico, randomizzato, di fase II, allo scopo di valutare il dosaggio di iniezioni multiple di THR-149 e di valutare l’efficacia e la sicurezza di THR-149 rispetto ad aflibercept nel trattamento dell’edema maculare diabetico (EMD) KALAHARI . STUDIO THR-149-002

• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR- CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION. STUDIO GR41986 – COMINO

• Retinal and cgnitive dysfuction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia . RECOGNISED

• Study Patient experience and preference  study in nAMD and DME . Studio MR41928_PEP

• One year, single arm, open label,multicenter,phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with Brolucizumab. study STUDIO CRTH258AIT04 IMAGINE

• AN EXPLORATORY, PROSPECTIVE,MULTI-CENTER, OPEN-LABEL, SINGLE-ARM,INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH FARICIMAB (RO6867461) – ALTIMETER STUDY

• A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA.  LONGITUDE STUDY

• TRATTAMENTO LASER SOTTOSOGLIA PER LE PSEUDODRUSEN RETICOLARI SECONDARIE A DEGENERAZIONE MACULARE LEGATA ALL’ETA’. STUDIO PASCAL – RPD

• Caratterizzazione della progressione della malattia retinica nei pazienti con retinopatia diabetica non proliferativa (npdr) nel diabete di tipo 2 utilizzando procedure non invasive.  Studio clinico: CHART

• “Studio di estensione, multicentrico e in aperto volto a valutare la sicurezza e la tollerabilità a lungo termine di FARICIMAB in pazienti con degenerazione maculare di tipo neovascolare legata all’età. AVONELLE -X _Studio clinico GR42691

• STUDIO DI FASE 3, MULTICENTRICO, IN DOPPIO CIECO, RANDOMIZZATO VOLTO A VALUTARE L’EFFICACIA E LA SICUREZZA DI OPT-302 INTRAVITREALE IN COMBINAZIONE CON AFLIBERCEPT, RISPETTO AD AFLIBERCEPT IN MONOTERAPIA, IN PARTECIPANTI CON DEGENERAZIONE MACULARE NEOVASCOLARE CORRELATA ALL’ETÀ (NAMD)” . Protocollo OPT-302-1005-COAST

• Studio di real world sulle terapie anti-vegf nella degenerazione maculare legata all’età di tipo neovascolare in Italia: analisi reale pratica clinica: Lo Studio Radiance.  ML43667-RADIANCE